OneSource Specialty Pharma Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The OneSource Specialty Pharma Q2 results FY27 announcement is the next scheduled earnings event for OneSource Specialty Pharma Ltd., a contract development and manufacturing company for specialty pharmaceuticals, focused on drug device combinations such as injectable pens and auto injectors, sterile injectables and biologics, demerged from its former parent and listed separately. The stock traded at Rs 1,616.80 on the NSE on 15 September 2026, up 1.55% from the previous close of Rs 1,592.20, about 16.0% below its 52-week high of Rs 1,925.00 and 53.0% above its 52-week low of Rs 1,057.00.

What makes the OneSource Specialty Pharma Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 376.00 crore of revenue and a profit of Rs 10.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 449.00 crore and a profit of Rs 25.00 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the OneSource Specialty Pharma Q2 Results FY27 Date?

The OneSource Specialty Pharma Q2 results date for FY27 is not confirmed. As of 15 September 2026, OneSource Specialty Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the OneSource Specialty Pharma Q2 results date becomes public through that filing rather than through any advance announcement.

The OneSource Specialty Pharma Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for OneSource Specialty Pharma.

OneSource Specialty Pharma Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the OneSource Specialty Pharma Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for OneSource Specialty Pharma. The OneSource Specialty Pharma Q2 results watchlist below is built from what the company has actually reported and disclosed.

The first is revenue, which was Rs 376 crore in September 2025 against Rs 449 crore in Q1 FY27, a rise of about 19%. Sales have been lumpy, falling to Rs 290 crore in December 2025 before rising for two quarters, which is normal for a contract manufacturer recognising revenue on batch despatch.

The second is the operating margin, which was 28% in September 2025 and 27% in Q1 FY27. December 2025 is the exception at 6%, where operating profit fell to Rs 17 crore on Rs 290 crore of sales and produced the Rs 89 crore net loss in that quarter.

The third is that the tax line is negative in all five quarters, at negative 96%, negative 83%, negative 5%, negative 1,630% and negative 23%. June 2026 net profit of Rs 25 crore would be closer to Rs 15 crore at a normal rate, so the reported recovery is partly a tax credit.

Check OneSource Specialty Pharma Ltd. Live Fundamentals on the Univest Screener

OneSource Specialty Pharma Q2 Results Preview: The Q1 FY27 Actuals It Builds On

OneSource Specialty Pharma Ltd. reported revenue of Rs 449.00 crore in Q1 FY27, up 37.31% from Rs 327.00 crore in Q1 FY26, and a profit of Rs 25.00 crore at the net level, a swing from a loss of Rs 0.00 crore in Q1 FY26 to a profit of Rs 25.00 crore. These are reported actuals, not estimates.

Sequentially, revenue was up 4.91% over the March 2026 quarter figure of Rs 428.00 crore, and net profit was up 400.00% from Rs 5.00 crore in Q4 FY26. Operating margin stood at 27% in Q1 FY27 against 28% in the September 2025 quarter, which is the comparison the OneSource Specialty Pharma Q2 results print will be read against.

Q2 FY26 Base: The Comparison OneSource Specialty Pharma Q2 Results FY27 Must Beat

OneSource Specialty Pharma Ltd. reported revenue of Rs 376.00 crore and a profit of Rs 10.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this OneSource Specialty Pharma Q2 results preview.

Net profit in that base quarter was below the Rs 25.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 376.00 crore sits below the Rs 449.00 crore of the June 2026 quarter, which frames how much sequential movement the OneSource Specialty Pharma Q2 results print needs to show growth.

OneSource Specialty Pharma Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	376.00	10.00
Q3 FY26 (Dec 2025)	290.00	(89.00)
Q4 FY26 (Mar 2026)	428.00	5.00
Q1 FY27 (Jun 2026)	449.00	25.00

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this OneSource Specialty Pharma Q2 results preview uses.

Revenue across those four quarters ranged from Rs 290.00 crore to Rs 449.00 crore, and net profit from Rs 89.00 crore loss to Rs 25.00 crore. That spread is the honest context for the OneSource Specialty Pharma Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape OneSource Specialty Pharma Q2 Results FY27

The OneSource Specialty Pharma Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what OneSource Specialty Pharma has already reported.

Depreciation Is the Dominant Cost Below the Line

It ran Rs 68 crore to Rs 72 crore in every quarter against operating profit of Rs 17 crore to Rs 123 crore, and interest added another Rs 23 crore to Rs 38 crore. That fixed charge is why a weak operating quarter turns straight into a large net loss.

Drug Device Combinations Are the Growth Piece

Injectable pens and auto injectors carry more value per unit than conventional sterile fill and finish, and capacity for them is what the depreciation charge represents. Utilisation of that capacity, rather than pricing, is what moves the margin here.

The Trailing Window Is Still a Loss

The last four quarters net to a loss of about Rs 49 crore because of the December 2025 quarter, so a price to earnings ratio is not shown. The share trades at 3.14 times book value of Rs 509.00 with borrowings giving a debt to equity ratio of 0.26.

OneSource Specialty Pharma Q2 Results FY27: Share Price and Valuation Going Into the Print

OneSource Specialty Pharma share price today is Rs 1,616.80 on the NSE, up Rs 24.60 or 1.55% from the previous close of Rs 1,592.20 on 15 September 2026, ahead of the OneSource Specialty Pharma Q2 results announcement.

Metric	Value (15 September 2026)
NSE Symbol	ONESOURCE
Current Market Price	Rs 1,616.80
52-Week High	Rs 1,925.00
52-Week Low	Rs 1,057.00
Market Capitalisation	Rs 18,539 crore
PE Ratio	Not meaningful on a trailing loss
PB Ratio	3.17
EPS (TTM)	Not meaningful on a trailing loss
Book Value per Share	Rs 509.00
Debt to Equity	0.26
Return on Equity	-1.09%
50-Day Moving Average	Rs 1591.47
200-Day Moving Average	Rs 1580.14
RSI (14)	64.18

The stock trades above both its 50-day average of Rs 1591.47 and its 200-day average of Rs 1580.14, with a 14-day RSI of 64.18. None of this is a view on where the shares go once the OneSource Specialty Pharma Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track OneSource Specialty Pharma Ltd. live price and quarterly earnings updates.

What Investors Should Watch When OneSource Specialty Pharma Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the OneSource Specialty Pharma Q2 results print in proportion.

1. Revenue against the Rs 376.00 crore reported in the September 2025 base quarter
2. Net profit against a profit of Rs 10.00 crore in that same quarter
3. Operating margin against 27% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the OneSource Specialty Pharma Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on OneSource Specialty Pharma Q2 Results FY27

The OneSource Specialty Pharma Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. OneSource Specialty Pharma Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the OneSource Specialty Pharma Q2 results FY27 print faces a base of Rs 376.00 crore in revenue and a profit of Rs 10.00 crore, with the most recent quarter having delivered Rs 449.00 crore and a profit of Rs 25.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for OneSource Specialty Pharma, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on OneSource Specialty Pharma Q2 Results FY27

What is the OneSource Specialty Pharma Q2 results date for FY27?

Ans. The OneSource Specialty Pharma Q2 results date for FY27 is not confirmed. OneSource Specialty Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 15 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the OneSource Specialty Pharma Q2 results 2026 cover?

Ans. The OneSource Specialty Pharma Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. OneSource Specialty Pharma Ltd. reports revenue, operating profit and net profit for that period, and the OneSource Specialty Pharma Q2 results filing also carries the notes to the accounts.

What were the OneSource Specialty Pharma Q1 FY27 results?

Ans. OneSource Specialty Pharma Ltd. reported revenue of Rs 449.00 crore in Q1 FY27 and a profit of Rs 25.00 crore at the net level. Revenue was up 37.31% versus Q1 FY26 and net profit was a swing from a loss of Rs 0.00 crore in Q1 FY26 to a profit of Rs 25.00 crore.

What were OneSource Specialty Pharma Q2 FY26 results in the September 2025 quarter?

Ans. OneSource Specialty Pharma Ltd. reported revenue of Rs 376.00 crore and a profit of Rs 10.00 crore in Q2 FY26. Operating margin was 28%. Those figures form the base for the OneSource Specialty Pharma Q2 results FY27 comparison.

What are the main OneSource Specialty Pharma Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The OneSource Specialty Pharma Q2 results expectations centre on revenue against the Rs 376.00 crore base, net profit against a profit of Rs 10.00 crore, operating margin against 27% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is OneSource Specialty Pharma share price today ahead of the Q2 earnings?

Ans. OneSource Specialty Pharma share price is Rs 1,616.80 on the NSE as of 15 September 2026, up 1.55% from Rs 1,592.20. The stock is about 16.0% below its 52-week high of Rs 1,925.00 and 53.0% above its 52-week low of Rs 1,057.00, at a market capitalisation of Rs 18,539 crore.

Is OneSource Specialty Pharma a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on OneSource Specialty Pharma Ltd. The stock trades at a price-to-book ratio of 3.17 with a return on equity of -1.09%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.